Telomerase promoter mutations in cancer: an emerging molecular biomarker?
about
Telomerase: The Devil InsideRoles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapiesVariations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancerThe search for cis-regulatory driver mutations in cancer genomesTelomerase Activation in Hematological MalignanciesTERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in TumorsFucoidan Induces ROS-Dependent Apoptosis in 5637 Human Bladder Cancer Cells by Downregulating Telomerase Activity via Inactivation of the PI3K/Akt Signaling Pathway.Raman spectroscopy using plasmonic and carbon-based nanoparticles for cancer detection, diagnosis, and treatment guidance.Part 1: Diagnosis.The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromesTelomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.Current status and future perspectives of fluorescence-guided surgery for cancer.TERT Promoter Mutations in Thyroid Cancer.TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.TERT Core Promotor Mutations in Early-Onset Bladder Cancer.Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.Evaluation of cannabinoid CB1 and CB2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.Hotspot TERT promoter mutations are rare events in testicular germ cell tumors.Whispering-Gallery Mode Resonators for Detecting Cancer.TERT promoter mutations and prognosis in solitary fibrous tumor.Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors.Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme.Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.Association between TERT rs2853669 polymorphism and cancer risk: A meta-analysis of 9,157 cases and 11,073 controls.Telomerase Reverse Transcriptase Polymorphism rs2736100: A Balancing Act between Cancer and Non-Cancer Disease, a Meta-Analysis.Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.Telomere Maintenance Mechanisms in Cancer.
P2860
Q26739948-DCA41155-2BE6-46C8-A2BF-0D26ED535A62Q26744271-093CA80E-C0C5-4E91-97D5-CE7C329269A1Q26775381-92629846-DFE9-4177-9126-223FF7FFC5CEQ26781886-D103DDFD-9861-4DE9-AD9B-920DE312DFD7Q28068238-C1981004-8248-4EFC-8EE0-387BD02803D0Q35711083-49376E07-ABD0-47D4-B542-4B62C246844FQ35811255-29E0155D-229A-41D6-907A-9657F365CDBEQ36139676-DFBDD51E-4CA1-40A1-BBA5-17E2EB07B272Q36298664-4D375AAB-0498-4F31-82CD-14CD9E99BFA1Q36729504-C84C0583-2056-4349-8435-52D6F44595AAQ37093384-A2A37CEF-16FC-4E72-86C3-70BC535A371BQ37317414-3C4CF7A9-FA97-4690-A3FF-DECE8D1E1168Q38331666-2667F03B-52CD-4B38-B1DE-932EA3F081C4Q38633227-B5E39B59-E3A3-4F40-86FA-312BA02EAB1CQ38744769-27DBC399-F4DC-4F09-AE73-D1A81EA4EFD1Q38774845-55A7522A-8FBB-41E8-959B-CD986F8251AFQ39676067-F07E8D64-77EE-4D9D-BFFE-084C7D2FF099Q40199208-F3E29A4E-9C32-48DB-A62F-A1FB1D9D80B1Q40440272-3204202E-71BF-4D3E-9AB0-3199525DB4BAQ40560920-887B486F-5BB2-440D-835B-2448E5106AEEQ40857012-2D86CE23-86ED-464E-B7DA-D7E3452FCA2CQ41156947-5A0FD9BC-D485-416E-A185-88E9F16A8CAFQ42223032-EBA38E60-42D8-4418-8E6E-F4199A3A2F75Q47147053-71D39EB7-44DD-4A80-B2D2-49A1954987D6Q47266315-885C9D34-C09D-4C1F-AA78-C3805D235228Q47646209-5701AB11-C392-4527-ADC4-004AC5BCA873Q48485483-DC6AB296-4737-460E-ACC9-26013FEC17CCQ49442455-E60F79FB-7D5A-46E5-989B-5A787E9D34DBQ49787884-0030EA36-DC90-4963-92F8-C17959A00FF3Q51304058-CC368F3B-4E0C-42FC-A807-D78D6BB021B6Q51415479-226E08C8-A626-485C-84B0-9AD0D5902BACQ52657990-298D4D9C-6942-45EE-8B7C-21BA17E5DA42Q52726708-56B1B4F6-3161-430B-BFFD-90ECC11EE040Q52727349-1CE88619-47D8-495B-AC27-A4AC50A85B63Q55443450-0628A439-D305-47E3-AF46-0E1D0A6279A6
P2860
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
@en
type
label
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
@en
prefLabel
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
@en
P2860
P50
P1433
P1476
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
@en
P2093
Valdemar Máximo
Vasco Pinto
P2860
P2888
P304
P356
10.1007/S00428-014-1608-4
P50
P577
2014-07-22T00:00:00Z